Beximco Group has yet again contributed towards the fight against COVID-19, however, this time the production took place via its subsidiary Nuvista Pharma. The company has manufactured the latest effective drug, dexamethasone, both in injection and tablet forms, which has been confirmed via a report of the BBC, to be effective against the novel coronavirus.
The report further revealed that Dexamethasone did not just cut the risk of death by a third of patients on ventilators but is also available at a reasonable price – making it easy for the patients to take the treatment in contrast to the expensive and congested treatments currently available in the market.
The name of Nuvista Pharma’s injection is Roxadex and the price per ampoule is only Tk 29, whereas the tablet name is Oradexon and its price is Tk 1.15 per tablet. In comparison, Beximco Pharmaceuticals’ another production “Remdesivir” costs about $65 per vial where a patient can require anywhere about 6-10 vials.
There are a few other companies as well in Bangladesh which manufacture and market dexamethasone under different brand names, nevertheless the price offered by Nuvista is laudable.
Beximco Group, a corporate giant, co-founded by Salman F Rahman, one of the most successful businessmen in Bangladesh, bought 85.22 per cent of shares of Nuvista Pharma in April 2018, about 12.92 % share is owned by the government of the country.
While talking with The Independent, Rabbur Reza, Managing Director of Nuvista Pharma, mentioned about the effectiveness of Dexamethasone against COVID-19 and the results are complemented by the University of Oxford.
Based on the results, he reveals that one death can be prevented by treatment of around eight ventilated patients with dexamethasone – making it one of the most inexpensive treatments available in the market for coronavirus.
For reference – http://www.theindependentbd.com/post/248401